Drugs for Neglected Diseases initiative
Antimicrobial resistance is a major challenge to reaching the SDGs and implementing UHC. The Interagency Coordination Group on Antimicrobial Resistance warns that there is no time to wait to act against this global crisis. It calls on all actors to act now “to increase investment and innovation in quality-assured, new antimicrobials (particularly antibiotics), novel compounds, diagnostics, vaccines”.
For research and development to make a real contribution to global health, a bench to bedside approach is needed, focusing on public health priorities, which ensures new and existing antibiotics are affordable, available, and used wisely.
We need urgent collective action. We welcome the creation of an ADG and Department for AMR. We urge countries to approve Resolution EB 144.R11, including its recommendations to support innovative approaches to R&D and mobilization of the human and financial resources necessary. There is also an urgent need to move discussions about access and stewardship from principles to practice, where all stakeholders have a critical role to play, including the Tripartite Plus and funders.
For its part, the Global Antibiotic Research and Development Partnership, initiated by WHO and Drugs for Neglected Disease initiative (DNDi), as an important element to deliver the Global Action Plan, will redouble its efforts, currently focused on developing antibiotics to treat children, neonates with sepsis and sexually transmitted infections, while integrating strategies for sustainable access. Later this year GARDP will launch an ambitious new strategy with expanded priorities.
But actions cannot stop here. Continued political commitment at the highest level is necessary including at the UN High level Meeting on Universal Health Coverage and the UN General Assembly in September 2019.